))
Top Research at SABCS 2024
Manage episode 455345086 series 3525104
Contenido proporcionado por Breastcancer.org. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Breastcancer.org o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
The 2024 San Antonio Breast Cancer Symposium featured five days of research presentations, educational sessions, and advocacy meetings.
Dr. Marisa Weiss, founder and chief medical officer of Breastcancer.org, breaks down the research that will have the most immediate impact for people diagnosed with breast cancer.
Listen to the episode to hear Dr. Weiss discuss:
- results from the PATINA study showing that adding Ibrance (chemical name: palbociclib) to first treatments for metastatic, hormone receptor-positive, HER2-positive breast cancer improved outcomes
- research on the benefits of risk-reducing surgery for young women with a BRCA mutation and a history of breast cancer
- the importance of moving away from a “one-size-fits-all” approach to treating breast cancer and personalizing treatments for each unique person
Scroll down to below the “About the guest” information to read a transcript of this podcast.
322 episodios
Compartir
